Mineralys Therapeutics (MLYS)

Executive Summary

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a novel, proprietary aldosterone synthase inhibitor for the treatment of hypertension, particularly in patients with uncontrolled blood pressure despite standard therapies. The company targets the renin-angiotensin-aldosterone system (RAAS), addressing a significant unmet need in the estimated 20-30% of hypertensive patients who are resistant to current treatments. Following its February 2023 IPO, Mineralys has advanced lorundrostat through late-stage clinical development, with a robust pipeline including Phase 2 and Phase 3 trials in hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company’s lean, remote-first structure supports efficient operations, and its lead program, the Phase 3 Advance-HTN trial (NCT05968430) in hypertension, is actively enrolling with completion expected in late 2026. Recent completed trials in CKD and OSA provide additional data supporting lorundrostat’s potential in broader cardio-renal-metabolic indications.

Upcoming Catalysts (preview)

• Q2 2026Presentation of Phase 2 data from lorundrostat in obstructive sleep apnea with hypertension (NCT06785454) at a major medical conference90% success
• Q2 2026Top-line results from Phase 2 chronic kidney disease trial (NCT06150924) – potential disclosure of final data or regulatory update85% success
• H2 2026Interim analysis or enrollment completion update for Phase 3 Advance-HTN trial (NCT05968430) in hypertension60% success